Capturing $51 Billion Opportunity in Global Cell and Gene Therapeutics
Building a Scalable, Commercial-ready Cell and Gene Therapy Ecosystem
Cell and gene therapy (CGT) developers are moving away from fragmented, manual processes and building integrated manufacturing and delivery ecosystems that combine automated platforms, digital batch records, and standardized regulatory guidance. This shift is creating a more scalable therapeutic environment that reduces production complexity, supports larger patient populations, and improves product consistency.
Our latest analysis shows how biotech companies, contract development and manufacturing organizations (CDMOs), and global regulators are adopting closed‑system manufacturing, advancing in vivo delivery platforms, and using regulatory accelerators like the Regenerative Medicine Advanced Therapy (RMAT), the Priority Medicines (PRIME) scheme, and Sakigake to shorten development timelines and improve commercial readiness.
Download Now
Ecosystem Snapshot
- Growth Drivers: Innovation in genome-editing tools, manufacturing transformation, evolving reimbursement models
- Companies to Action: Gilead Sciences, Novartis, Bristol Myers Squibb, Johnson & Johnson, Roche
- Key Technologies: In vivo gene editing platforms, scalable allogeneic CAR-T engineering, automated “lights-out” CGT manufacturing
Are you equipped to deliver consistent, scalable, and commercially ready cell and gene therapies to broader patient populations?
Advancing Cell and Gene Therapy Commercialization — Frost & Sullivan Has You Covered With:
- Strategies to address barriers to commercial scale, including high therapy prices, complex manufacturing, and concerns about long-term safety and durability.
- Technology megatrends like early genomic screening, AI-enabled patient finding and trial matching, and digital long-term follow-up that broaden patient pools and streamline clinical and commercial workflows.
- Strategic partnerships that combine advanced vector platforms with scalable Good Manufacturing Practice (GMP) manufacturing and global development to move programs forward efficiently.
Discover the competitive dynamics, regional insights, and strategic growth opportunities shaping cell and gene therapy commercialization.
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
Upon completing the dialog session, you will receive a $1,000 honorarium as a token of our appreciation, which can be used towards the purchase of our products or services.
